Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.
This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.
The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.
- Have increased knowledge regarding the emerging clinical trials data on the use of immune-modulating agents in the management of melanoma
- Have increased knowledge regarding the place in therapy for immune checkpoint inhibitors in patients with melanoma
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 4, 2020 - Mar. 4, 2021
Developed through a partnership between SITC and Medscape.
Additional Melanoma Resources for Clinicans from SITC: